Australia's CSL reports 2% fall in annual profit
CSL to start clinical trials for new immunoglobulin manufacturing process
Australia says CSL unit Seqirus to discontinue Benpen injections from November
CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
Australian biopharma firm CSL posts 14% rise in annual profit